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Darren Klass, MD, PhD, and David Liu, MD, Vancouver, British Columbia, Canada
An unstable patient presented with an enlarging splenic hematoma, for whom splenectomy was contraindicated. The
decision was made to treat this patient with subtotal splenic embolization. Initial attempts at embolotherapy using a
conventional end-hole catheter resulted in a false angiographic end point with reﬂux into short gastric arteries, likely due
to splenic parenchymal pressurization from the hematoma. The Sureﬁre antireﬂux device (Sureﬁre Medical Inc, West-
minster, Colo) was therefore employed. The Sureﬁre device allowed successful subtotal splenic embolization. Whereas it is
currently primarily used in hepatic interventional oncology, we have shown that it can be successfully used in other
settings to increase embolization efﬁciency while mitigating nontargeted embolization. (J Vasc Surg Cases 2015;1:242-5.)Transcatheter embolization is an accepted standard of
care in the treatment of numerous visceral pathologic pro-
cesses ranging from trauma to neoplasia. A unique
circumstance arises when a space-occupying entity de-
velops adjacent to and exerts mass effect on a solid organ
that requires embolization, such as can be seen when a
hemorrhaging renal angiomyolipoma results in a large
perinephric hematoma. This may result in elevated paren-
chymal pressurization of the organ, increasing the likeli-
hood of incomplete embolization as well as nontargeted
embolization. We present such a scenario, in which a pa-
tient with an enlarging subcapsular splenic hematoma
required subtotal splenic embolization, and discuss the
novel use of the Sureﬁre antireﬂux device (Sureﬁre Med-
ical Inc, Westminster, Colo) to overcome the limits of
conventional end-hole catheter embolotherapy. The pa-
tient’s consent for potential publication of his therapy
was obtained.
CASE REPORT
A 50-year-old white male Jehovah’s Witness presented to a
peripheral hospital with an 8-day history of abdominal pain and
in hypovolemic shock. Initial assessment including standard
biochemical markers and computed tomography (CT) revealed
a history compatible with acute-on-chronic pancreatitis compli-
cated by a large subcapsular splenic hematoma. This is a known
albeit rare complication of pancreatitis that has been describedthe Department of Radiology, University of British Columbia.
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://dx.doi.org/10.1016/j.jvsc.2015.07.005in the literature.1,2 A multiphase CT examination at our institu-
tion demonstrated further enlargement of the splenic hema-
toma, although there was no evidence of active arterial
extravasation.
Because of ongoing hemodynamic instability, worsening
symptoms, enlargement of the hematoma, and a contraindication
to splenectomy due to concerns of potential blood loss coupled
with the patient’s refusal to receive blood products because of
his religious beliefs, the decision was made by his clinical team to
proceed with pre-emptive subtotal splenic embolization.
TECHNIQUE
After ﬂuid resuscitation, informed consent was ob-
tained and moderate sedation was initiated. The right com-
mon femoral artery was accessed, and a 45-cm Ansel 2
vascular sheath (Flexor; Cook Medical Inc, Bloomington,
Ind) was placed. A 100-cm C2 glide catheter (Terumo
Medical Corporation, Somerset, NJ) and hydrophilic wire
(Terumo Medical Corporation) were used to select the
splenic artery to near the splenic hilum. A focal non-ﬂow-
limiting dissection was inadvertently created during cath-
eter placement, which was successfully navigated across
(Fig 1, a).
After administration of half of a vial of 100- to 300-
mm Bead Block particles (Biocompatibles Inc, Oxford,
Conn), apparent stasis was achieved, with injected
contrast material reﬂuxing into adjacent short gastric ar-
teries (Fig 1, b). Such an early apparent end point was
not typical of our usual experience, and with such a low
volume of delivered embolic, it was highly unlikely that
much splenic tissue had been truly embolized. The situa-
tion was most compatible with a false angiographic end
point from splenic parenchymal pressurization due to
the subcapsular hematoma.
As a result, exchange and subsequent introduction of a
Sureﬁre LT proximal protection device through a 65-cm
5F Axis catheter (Sureﬁre Medical Inc) with a 180-cm
Fathom-16 guidewire (Boston Scientiﬁc, Natick, Mass)
was performed with the intent of improving embolic deliv-
ery efﬁciency (Fig 1, c and d).
Fig 1. Splenic artery angiographic appearances before any embolization (a) and after administration of half a vial of
100- to 300-mm Bead Block particles through an end-hole catheter (b), showing apparent subtotal splenic emboli-
zation with truncation of distal splenic branches and proximal reﬂux into short gastric arteries (arrow). Positioning of a
Sureﬁre antireﬂux infusion catheter into the splenic artery undeployed (c) and with the expandable tip deployed
(d; arrow). Residual small dissection in the mid splenic artery (arrowhead).
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vials of 100- to 300-mm Bead Block particles and 1 vial
of 300- to 500-mm Embosphere particles (Merit Medical
Systems Inc, South Jordan, Utah) were delivered without
evidence of reﬂux (Fig 2, a). After sluggish ﬂow was
perceived within the more central splenic branches, embo-
lization was ceased. Contrast-enhanced cone beam CT was
performed on the procedural table; this showed persistent
patchy enhancement of a minority of splenic tissue and
veriﬁed that a subtotal splenic embolization (rather than
complete splenic embolization) was successfully achieved
(Fig 2, b). The procedure was completed with no immedi-
ate complications. A vascular closure device was used to
achieve hemostasis.
A CT examination performed 5 days later demon-
strated successful subtotal splenic embolization, with noincrease in size of the hematoma, indicating technical suc-
cess (Fig 2, c and d).
DISCUSSION
Transcatheter splenic artery embolization is an
accepted standard of care in the treatment of numerous
splenic pathologic processes, including post-traumatic and
postinﬂammatory splenic hemorrhages.3-5 Two widely
accepted methods are used, proximal splenic artery embo-
lization and subtotal (ie, partial) splenic embolization.5
The rationale for proximal splenic artery embolization is
based on the concept that eliminating ﬂow from the
main splenic artery will reduce splenic arterial pressure to
the point at which foci of hemorrhage will cease while
collateral branches continue perfusing the spleen to main-
tain splenic function. However, this method is limited in
Fig 2. a, Angiographic appearance during Sureﬁre infusion system-aided administration of an additional 2.5 vials of
100- to 300-mm Bead Block particles and 1 vial of 300- to 500-mm Embosphere particles. No reﬂux was seen into short
gastric arteries. b, Axial image from postembolization contrast-enhanced cone beam computed tomography (CT)
performed on the procedural table, showing persistent patchy splenic parenchymal enhancement compatible with
subtotal splenic embolization. c, Axial image from a preprocedural contrast-enhanced CT study revealing a large
subcapsular splenic hematoma. d, Axial image from a contrast-enhanced CT study obtained 5 days after embolization
shows substantially reduced splenic parenchymal enhancement (arrow), although some residual viable splenic tissue was
depicted, indicating successful subtotal splenic embolization.
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artery embolism precludes any additional splenic artery
embolization interventions and surgical splenectomy will
be required. Alternatively, the goal of subtotal emboliza-
tion is to achieve distal splenic arterial branch embolization
wherein anywhere from 50% to 80% of splenic tissue is
embolized, leaving a small amount of residual splenic tissue
to maintain splenic function. The main limitation of subto-
tal splenic embolization is that small areas of splenic infarct
are more likely, which have the potential to later become
infected. However, its advantages over the former method
include greater likelihood of embolizing distal hemor-
rhages and allowing additional splenic embolization proce-
dures if necessary.
In the example outlined in this report, the most likely
origin for the patient’s subcapsular hematoma was from a
peripheral splenic branch eroded by adjacent pancreatitis-related inﬂammation. This, combined with the fact that
the patient did not realistically have the option of splenec-
tomy in case embolization failed, made the choice for sub-
total splenic embolization more favorable than proximal
splenic artery embolization.
The case represents a situation in which the presence of
a large, contained perisplenic hematoma resulted in ineffec-
tive embolization through a traditional end-hole catheter
and increased the likelihood of nontargeted embolization.
The Sureﬁre infusion system (Fig 3) is an antireﬂux device
that has recently been brought to market and has primarily
been applied in transarterial hepatic interventional
oncology.6 In the liver, its primary role is a prophylactic
onedto eliminate the risk of reﬂux and nontargeted
embolization when agents such as yttrium 90-loaded mi-
crospheres are delivered, as even minuscule amounts of
such substances reﬂuxing into vessels supplying the
Fig 3. Illustration of the distal expandable tip of the Sureﬁre infusion catheter, with its various components labeled (see
http://sureﬁremedical.com/products/sureﬁre-infusion-system-mt-lt).
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Herein, we describe an indication and application of the
Sureﬁre infusion system in which the primary intent was
to optimize embolic load delivery and to increase emboli-
zation efﬁciency, with mitigation of nontargeted emboliza-
tion a secondary although still important outcome.
To brieﬂy outline the use of the Sureﬁre system, an
appropriate guiding catheter is ﬁrst used that can accom-
modate the Sureﬁre system (inner diameter >0.051
inch). The Sureﬁre infusion catheter is then preloaded
with a guide microwire (0.014-0.018 inch). Together,
the Sureﬁre catheter and guidewire are advanced through
the guiding catheter to a position where initiation of
embolic infusion is desired. The outer sheath of the Sure-
ﬁre catheter is then retracted under ﬂuoroscopy until its
expandable tip deploys and the radiopaque marker on the
outer sheath is proximal to the radiopaque marker at the
base of the expanded tip. Embolic delivery is then
commenced. Because of the design of the expandable tip,
when antegrade blood ﬂow is present, the tip partially col-
lapses to allow incoming blood to carry the embolic load
distally; when retrograde ﬂow is present, the expandable
tip opens fully to mitigate any unintended reﬂux of embolic
material.7 Consequently, gradually reduced antegrade ﬂow
can be readily observed during embolization with the Sure-
ﬁre catheter, allowing greater ease in estimating when a
satisfactory end point has been reached.
Rose et al8 have in the past described the use of tempo-
rary splenic artery balloon occlusion to protect against
nontarget embolization during splenic embolotherapy. A
key disadvantage with temporary balloon occlusion
compared with the Sureﬁre system is that antegrade ﬂow
is often lost during the duration of balloon occlusion. As
a result, the embolic load is more likely to stay deposited
near the catheter tip unless saline is used to ﬂush it distally,
and assessing for a satisfactory end point becomes more
difﬁcult, with the possibility of inadvertently overemboliz-
ing and achieving unintended total splenic embolization
becoming greater.CONCLUSIONS
We have described a novel application of the Sureﬁre
antireﬂux device as a tool to greatly improve embolotherapy
efﬁciency in subtotal embolization of the spleen, where
traditional end-hole catheter embolotherapy was ineffective.
Given its advantage of increasing embolization efﬁciency
while at the same time mitigating nontargeted embolization,
we believe this device has a role in solid visceral embolization
(particularly in circumstances in which parenchymal pressur-
ization is increased) beyond its current, primarily prophylac-
tic application in hepatic oncology.
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